Bavarian Nordic To Raise $250m For Phase III RSV Vaccine Study
Self-Funded Trial To Begin Next Year
The firm anticipates a late-stage study of MVA-BN RSV in the first half of 2022
You may also be interested in...
Johnson & Johnson has impressed with its Phase II data but Pfizer and GSK have both already begun their Phase III studies.
Solid Phase II data for Bavarian Nordic’s investigational vaccine MVA-BN RSV showed falls in both symptoms and viral load of respiratory syncytial virus in the challenge trial’s adult participants, boosting prospects for a Phase III trial - and for finding a commercial partner.
Phase II trials of Bavarian Nordic’s MVA-BN RSV prophylactic vaccine suggest it boosts memory responses against RSV in patients with a poor underlying immunity. Phase III trials may begin in 2020.